Penumbra to Highlight Importance of Stroke Treatment at Upcoming Patient Awareness Events

ALAMEDA, Calif. –
Penumbra,
Inc. (NYSE:PEN), a global interventional therapies company, today
announced a series of events in New York City aimed to raise awareness
for stroke treatment, coinciding with the one-year anniversary of the
company’s initial public offering. Stroke remains an undertreated
disease, and the events aim to bring attention to the importance of
getting patients to hospitals in time for endovascular treatment.

Together with stroke patients who represent over 20 U.S. states and were
treated with the Penumbra System^®, the company will
participate in the following events:

• Stroke Awareness Day at Yankee Stadium – Sept.
  28: Penumbra will sponsor a stroke treatment awareness event
  organized by The Joe Niekro Foundation™ during the Boston Red Sox vs.
  New York Yankees game at Yankee Stadium. The Joe Niekro Foundation™ is
  committed to supporting stroke patients and families, research,
  treatment and awareness. The event will pay tribute to and honor
  stroke patients with the goal of highlighting the importance of timely
  treatment. Stroke patients will be recognized on the field before the
  game and a public service announcement will be shared as part of the
  event.
• NYSE Bell Ringing – Sept. 29: To
  commemorate the one-year anniversary of Penumbra’s initial public
  offering, the company and the New York Stock Exchange are inviting
  stroke patients to ring the opening bell.
• A Cerebral Affair – Sept. 29: Penumbra is
  a platinum sponsor of the “A Cerebral Affair” fundraising gala, hosted
  by The Lisa Colagrossi Foundation and The Joe Niekro Foundation™. The
  event aims to benefit awareness and research for brain aneurysms, a
  potential cause for hemorrhagic stroke.

“Penumbra is honored to bring patients together from all over the
country to draw attention to the critical issue that treatable stroke
patients need to get to the right hospitals for access to endovascular
stroke treatment,” said Adam Elsesser, chairman and chief executive
officer of Penumbra. “When these patients get to the right hospital, the
benefit can be profound and life changing for the patients and their
families.”

Important Facts about Stroke and Stroke Treatment

• About every four minutes, one American dies from a stroke – a brain
  attack caused by a ruptured or blocked artery.
• Stroke is the fifth leading cause of death and a leading cause of
  disability in the U.S.
• Advances in stroke treatments – including endovascular treatment,
  which acts like a minimally invasive “vacuum” to remove the blood clot
  inside the blocked artery in the brain – are leading to better
  survival and quality of life.
• Only about 10 percent of patients receive endovascular treatment
  because others don’t arrive in time to the right stroke centers that
  offer the procedure.
• Several published studies, including the landmark MR CLEAN study in
  the New
  England Journal of Medicine, showed that endovascular
  treatment is a superior treatment option compared to the clot-busting
  drug tPA.
• By knowing the signs of stroke and acting F-A-S-T (Face drooping, Arm
  weakness, Speech difficulty and Time to call 911), stroke victims can
  get timely treatment and are twice as likely to survive.

About Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global
interventional therapies company that designs, develops, manufactures
and markets innovative medical devices. The company has a broad
portfolio of products that address challenging medical conditions and
significant clinical needs across two major markets, neuro and
peripheral vascular. Penumbra sells its products to hospitals primarily
through its direct sales organization in the U.S., most of Europe,
Canada and Australia, and through distributors in select international
markets. Penumbra, Penumbra System and the Penumbra logo are trademarks
of Penumbra, Inc. For further information, please visit www.penumbrainc.com.

Forward-Looking Statements

Except for historical information, certain statements in this press
release are forward-looking in nature and are subject to risks,
uncertainties and assumptions about us. Our business and operations are
subject to a variety of risks and uncertainties and, consequently,
actual results may differ materially from those projected by any
forward-looking statements. Factors that could cause actual results to
differ from those projected include, but are not limited to: failure to
sustain or grow profitability or generate positive cash flows; failure
to effectively introduce and market new products; delays in product
introductions; significant competition; inability to further penetrate
our current customer base, expand our user base and increase the
frequency of use of our products by our customers; inability to achieve
or maintain satisfactory pricing and margins; manufacturing
difficulties; permanent write-downs or write-offs of our inventory;
product defects or failures; unfavorable outcomes in clinical trials;
inability to maintain our culture as we grow; fluctuations in foreign
currency exchange rates; and potential adverse regulatory actions. These
risks and uncertainties, as well as others, are discussed in greater
detail in our filings with the Securities and Exchange Commission,
including our Quarterly Reports on Form 10-Q and our Annual Report on
Form 10-K for the year ended December 31, 2015. There may be additional
risks of which we are not presently aware or that we currently believe
are immaterial which could have an adverse impact on our business. Any
forward-looking statements are based on our current expectations,
estimates and assumptions regarding future events and are applicable
only as of the dates of such statements. We make no commitment to revise
or update any forward-looking statements in order to reflect events or
circumstances that may change.

Note to Editors: Interviews with stroke patients are available.
Images and a PSA video will be available following the events.

Source: Penumbra, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160927005340/en/

Merryman Communications
Betsy Merryman
310-560-8176
[email protected]